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Mycoplasma pneumoniae causes community-acquired respiratory tract infections,
particularly in school-aged children and young adults. These infections occur both
endemically and epidemically worldwide. M. pneumoniae lacks cell wall and is
subsequently resistant to beta-lactams and to all antimicrobials targeting the cell wall.
This mycoplasma is intrinsically susceptible to macrolides and related antibiotics, to
tetracyclines and to fluoroquinolones. Macrolides and related antibiotics are the first-line
treatment of M. pneumoniae respiratory tract infections mainly because of their low
MIC against the bacteria, their low toxicity and the absence of contraindication in
young children. The newer macrolides are now the preferred agents with a 7-to-14
day course of oral clarithromycin or a 5-day course of oral azithromycin for treatment
of community-acquired pneumonia due to M. pneumoniae, according to the different
guidelines worldwide. However, macrolide resistance has been spreading for 15 years
worldwide, with prevalence now ranging between 0 and 15% in Europe and the USA,
approximately 30% in Israel and up to 90–100% in Asia. This resistance is associated with
point mutations in the peptidyl-transferase loop of the 23S rRNA and leads to high-level
resistance to macrolides. Macrolide resistance-associated mutations can be detected
using several molecular methods applicable directly from respiratory specimens.
Because this resistance has clinical outcomes such as longer duration of fever, cough
and hospital stay, alternative antibiotic treatment can be required, including tetracyclines
such as doxycycline and minocycline or fluoroquinolones, primarily levofloxacin, during
7–14 days, even though fluoroquinolones and tetracyclines are contraindicated in all
children and in children <8 year-old, respectively. Acquired resistance to tetracyclines
and fluoroquinolones has never been reported in M. pneumoniae clinical isolates but
reduced susceptibility was reported in in vitro selected mutants. This article focuses on
M. pneumoniae antibiotic susceptibility and on the development and the evolution of
acquired resistance. Molecular detection of resistant mutants and therapeutic options in
case of macrolide resistance will also be assessed.
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INTRODUCTION
Mycoplasma pneumoniae is responsible for community-
acquired respiratory tract infections, such as tracheobronchitis
and pneumonia, particularly in school-aged children and
young adults. These infections occur both endemically and
epidemically at 3-to-7-year intervals worldwide (Atkinson et al.,
2008). Numerous extra-respiratory manifestations of variable
severity have also been associated withM. pneumoniae infections
including dermatological manifestations and neurological
complications. Before 2000, M. pneumoniae infections were
easily treated using macrolides because only rare cases of
resistance to macrolides had been reported in clinical isolates.
Since 2000, macrolide resistance rates have been rising up to
90–100% in Asia, hindering the efficacy of common antibiotic
regimens.
This mini-review focuses on M. pneumoniae intrinsic
resistance, antibiotic susceptibility and on the development
and the evolution of acquired macrolide resistance worldwide
since the last published review (Bébéar et al., 2011). Methods
for molecular detection of macrolide resistance-associated
mutations and therapeutic options in case of infections with
macrolide-resistantM. pneumoniae strains are also assessed.
ACTIVE ANTIBIOTICS AND INTRINSIC
RESISTANCE
Like all microorganisms that lack cell wall, M. pneumoniae is
intrinsically resistant to beta-lactams and to all antimicrobials
targeting the cell wall, such as glycopeptides and fosfomycin.
M. pneumoniae is also resistant to polymixins, sulfonamides,
trimethoprim, rifampicin and linezolid (Bébéar and Kempf,
2005; Bébéar et al., 2011). Antibiotics with potential activity
against M. pneumoniae that are used in clinical practice
include macrolides, lincosamides, streptogramin combinations
and ketolides (MLSK), tetracyclines and fluoroquinolones. These
drugs achieve high intracellular concentration in mammalian
cells and are thereby able to reach intracellular mycoplasmas. The
MICs of the main antibiotics belonging to the MLSK group are
the lowest against M. pneumoniae compared with those of the
two other classes, except MIC of lincomycin that is high (seeMIC
of the sensitive reference strain M129 (ATCC 29342) in Table 1;
Bébéar et al., 2011). MICs of tetracyclines and fluoroquinolones
are about 10 times higher than those of MLSK, but newer
fluoroquinolones such as levofloxacin and moxifloxacin show an
enhanced activity againstM. pneumoniae.Only fluoroquinolones
and ketolides have a potential bactericidal action. Other
antibiotics such as aminoglycosides and chloramphenicol show
some activity against M. pneumoniae (MICs 2–10 µg/ml for
chloramphenicol and MIC 4 µg/ml for gentamicin, Bébéar et al.,
2011) but are not recommended forM. pneumoniae infections.
The in vitro activity of a few new agents was recently reported.
AZD0914, a spiropyrimidinetrione DNA gyrase inhibitor,
showed a MIC90 of 1 µg/ml, comparable to that of levofloxacin
(Waites et al., 2015). ACH-702, a novel isothiazoloquinolone,
and BC-3781, a semi-synthetic pleuromutilin antibiotic, showed TA
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FIGURE 1 | Peptidyltransferase loop of domain V of 23S rRNA of Mycoplasma pneumoniae (Escherichia coli numbering) with nucleotides found
mutated in in vitro-selected strains and in clinical isolates of macrolide-resistant M. pneumoniae. Adapted from Bébéar et al. (2011). Squared nucleotides
indicate positions mutated in in vitro-selected macrolide resistant mutants. Antibiotics used for in vitro selection are in parentheses (14M, 14-membered macrolides;
15M, 15-membered macrolides; 16M, 16-membered macrolides; SC, streptogramin combinations; K, ketolides). Circled nucleotides indicate positions mutated in
clinical macrolide resistant isolates.
better MICs, comparable to those of MLSK, with MIC90 of 0.015
and 0.006 µg/ml, respectively (Pucci et al., 2011; Sader et al.,
2012).
MECHANISMS OF M. PNEUMONIAE
ACQUIRED RESISTANCE AND
RESISTANCE MOLECULAR DETECTION
METHODS
In M. pneumoniae, only antimicrobial target modifications
by acquired mutations have been associated with antibiotic
resistance (Bébéar and Pereyre, 2005). The high mutation rates
and the small amount of genetic information dedicated to
DNA repair in mycoplasmas (Rocha and Blanchard, 2002) may
be associated with this single mode of antibiotic resistance.
Resistance through mutation was reported in in vitro-selected
mutants for all three classes of antibiotics used to treat
M. pneumoniae whereas to date, resistance in clinical isolates was
only reported for the MLSK antibiotic class.
Acquired Resistance to Macrolides and
Related Antibiotics
Macrolide resistance in the M. pneumoniae species, which
harbors only one ribosomal operon, is defined by mutations
in the ribosomal target of the antibiotic, i.e., the 23S rRNA
and the ribosomal proteins L4 and L22 (Bébéar and Pereyre,
2005; Bébéar et al., 2011). The A2058G (Escherichia coli
numbering) transition in the peptidyltransferase loop of domain
V of 23S rRNA is the most common mutation that is
associated with macrolide resistance (Figure 1, Table 2). Other
substitutions have been reported at position 2058 (A2058C,
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A2058T), at position 2059 (A2059G, A2059C), at position
2062 (A2062G) and at position 2611 (C2611G, C2611A). No
mutation has been detected in domain II of 23S rRNA.
Mutations in conserved regions of ribosomal L4 and L22
proteins such as single amino acid change, insertion and
deletion of amino acids have also been associated with low-
level macrolide resistance in in vitro selected mutants (Pereyre
et al., 2004a). Rare mutations have been reported in vivo
in ribosomal proteins L4 and L22 but were not associated
with significant increased MICs of macrolides (Cao et al.,
2010). Comparison of sequencing results with antimicrobial
susceptibility testing confirmed that mutations A2058G and
A2059G led to a high level resistance to 14- and 15-
membered macrolides and lincosamides (Xin et al., 2009;
Cao et al., 2010; Akaike et al., 2012; Zhao et al., 2013b;
Table 1). Whereas 16-membered macrolides were highly
affected by the A2059G substitution, the A2058G mutation
was associated with an intermediate level of resistance to these
antibiotics. Mutations at position 2611 were associated with low-
level of resistance to MLSK. Interestingly, the streptogramin
combinations, quinupristin-dalfopristin and pristinamycin, and
the ketolide solithromycin (CEM-101) retained activity on
resistant mutants harboring mutations at position 2058, 2059,
and 2611 (Pereyre et al., 2007; Waites et al., 2009; Table 1).
However, an in vitro mutant selection study showed that the
A2062G transition was associated with significant increased
MICs of these two streptogramin combinations (Pereyre et al.,
2004a).
Cross-resistance was not observed between MLSK and other
antibiotic families commonly used against M. pneumoniae
because isolates with macrolide resistance-associated mutations
remain susceptible to tetracyclines and fluoroquinolones
(Table 1).
Several molecular methods applicable directly on respiratory
specimens were developed to detect macrolide resistance and
to circumvent the fastidious, insensitive and time-consuming
isolation of M. pneumoniae from clinical samples. Apart from
the conventional amplification and sequencing of the hot spots
of the 23S rRNA gene, macrolide resistance determination
was achieved by PCR-restriction fragment lengh polymorphism
(Matsuoka et al., 2004), real-time PCR and melting curve
analysis (Peuchant et al., 2009), pyrosequencing (Spuesens
et al., 2010, 2012) and real-time PCR and high resolution
melt (HRM) analysis (Wolff et al., 2008). A nested-PCR
combined with single-strand conformation polymorphism and
capillary electrophoresis (Lin et al., 2010) and a singe nucleotide
polymorphism (SNP) PCR assay (Ji et al., 2014) were also
developed to detect macrolide-resistant mutants directly from
clinical specimens. Most of these in-house approaches allow
resistance screening in M. pneumoniae-positive respiratory tract
samples but the clinical sensitivity i.e., the proportion of
M. pneumoniae-positive specimens capable of being resistance
typed varies according to methods, ranging between 72.6 and
80.2% in the studies where it was calculated (Wolff et al.,
2008; Peuchant et al., 2009; Spuesens et al., 2012). The need
to perform such tests differs according to the prevalence of
macrolide resistance in each country. In countries where the
percentage of macrolide resistance is over 10%, it could be
recommended that all M. pneumoniae detection be followed
up with an assay capable of detecting macrolide resistance-
associated mutations. This strategy would allow a non-macrolide
treatment to be promptly started in the event that a macrolide-
resistant genotype is detected in an individual patient. In
contrast, in countries where macrolide resistance remains below
10%, this kind of test could be performed only in case of
treatment failure.
Currently, this strategy is hampered by the lack of
commercially available sensitive kits that detect macrolide
resistance-associated mutations. However, such kits are currently
in development and may soon become available. They will be
useful for routine diagnostics in microbiology laboratories.
Acquired Resistance to Tetracyclines and
Fluoroquinolones
To date, no tetracycline or fluoroquinolone resistance has been
reported in M. pneumoniae clinical isolates. However, resistant
strains have been selected in vitro for both classes of drugs. Target
mutations were identified in the 16S rRNA gene of tetracycline-
resistant mutants selected with subinhibitory concentrations
of doxycycline. Mutations were associated with reduced
susceptibility to tetracycline, doxycycline and minocycline
with MICs remaining below ≤2 µg/ml (Degrange et al.,
2008). Mutations within conserved regions of the gyrA, gyrB,
parC, and parE genes referred to as the quinolone resistance-
determining regions were reported for fluoroquinolone-resistant
mutants selected with different fluoroquinolones and were
associated with MICs of ciprofloxacin, levofloxacin and
moxifloxacin up to 32, 16, and 4 µg/ml, respectively (Gruson
et al., 2005). Mutations rates were low for levofloxacin and
moxifloxacin, ranging from 1.3 × 10−6 to 7 × 10−9 (Gruson
et al., 2005).
PREVALENCE OF MACROLIDE
RESISTANCE IN M. PNEUMONIAE
Recent rates of macrolide resistance in M. pneumoniae clinical
isolates in countries in which publications have been released
since the last review (Bébéar et al., 2011) are presented in
Table 2. Prior to the year 2000, very few M. pneumoniae clinical
isolates were resistant to macrolides. Rare strains resistant to
erythromycin were reported in the literature between 1968 and
1999 in Japan, Israel, Finland, USA and France (Niitu et al.,
1970; Stopler and Branski, 1986; Critchley et al., 2002; Pereyre
et al., 2007). By contrast, several Japanese studies have reported
a significant and constant increase in macrolide resistance
rates since 2000, reaching 30% in 2006, around 60% in 2009
and up to 89% in 2010–2011 (Morozumi et al., 2008; Okada
et al., 2012; Matsuda et al., 2013). However, regional differences
in rates of macrolide-resistant M. pneumoniae were recently
reported in Japan, for example in Hokkaido island, where
rates ranged from 0 to 100% according to regions (Ishiguro
et al., 2015). The situation is worse in China where a dozen
of articles have reported a prevalence of macrolide resistance
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TABLE 2 | Prevalence of macrolide resistance in M. pneumoniae clinical isolates (continents and countries are presented in alphabetical order).
Country Year % of macrolide resistance (number of resistant
strains or M. pneumoniae-positive
specimens/total strains or specimens tested)
23S rRNA mutations
(%)
References
AMERICA
Canada (Ontario) 2010–2012 12.1% (11/91) A2058G (91%) Eshaghi et al., 2013
A2059G (18%)
USA (14 states) 2006–2013 10.8% (19/176) ND Diaz et al., 2015b
USA (St. Louis, Missouri) 2010–2012 8.2% (4/49) A2058G (100%) Yamada et al., 2012
USA (3 states) 2010–2012 3.5% (7/202) A2058G (85.7%) Diaz et al., 2015a
A2059G (14.3%)
USA (6 states) 2012–2014 13.2% (12/91) A2058G (100%) Zheng et al., 2015
ASIA
China (Beijing) 2003–2006 92% (46/50) A2058G (86.9%) Xin et al., 2009
A2058C (2.2%)
A2059G (10.9%)
China (Shanghai) 2005–2009 90.1% (137/152) ND Liu et al., 2012
China (Beijing) 2008–2009 69% (46/67) A2058G (89.1%) Cao et al., 2010
A2059G (8.7%)
A2058T (2.2%)
China (Shanghai) 2008–2009 90% (90/100) A2058G (98%) Liu et al., 2010
A2058T (1%)
A2059G (1%)
China (Beijing) 2008–2011 88.1% (177/201) A2058G (96.6%) Zhao et al., 2013a
A2059G (2.8%)
A2059T (0.6%)
China (Beijing) 2008–2012 90.7% (280/309) A2058G (97.1%) Zhao et al., 2013b
A2059G (2.5%)
A2058T (0.4%)
China (Beijing) 2009 91% (58/64) A2058G (98.3%) Lin et al., 2010
A2058T (1.7%)
China (Beijing) 2010–2012 90.8% (59/65) A2058G (100%) Sun et al., 2013
China (Beijing, Dongcheng,
Xicheng)
2011 95% (38/40) A2058G (97%) Zhao et al., 2011
A2059G (3%)
China (Zhejiang province) 2012–2014 100% (71/71) A2058G (100%) Zhou et al., 2015
China (Beijing) 2013 98.5% (128/130) A2058G (100%) Yan et al., 2014
Hong-Kong 2011 13.6% (3/22) A2058G (100%) Ho et al., 2015
2012 30.7% (23/75)
2013 36.6% (34/93)
2014 47.1% (24/51)
Japan (65 institutions) 2008 56% (9/16) A2058G (95.9%)* Kawai et al., 2013
2009 69% (9/13) A2058T (3.2%)
(Continued)
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TABLE 2 | Continued
Country Year % of macrolide resistance (number of resistant
strains or M. pneumoniae-positive
specimens/total strains or specimens tested)
23S rRNA mutations
(%)
References
2010 71% (79/110) A2059G (0.5%)
2011 63% (176/281) A2058C (0.2%)
2012 82% (288/349) C2611G (0.2%)
Japan (Fukuoka prefecture) 2010–2011 89.2% (58/65) A2058G (53%) Matsuda et al., 2013
A2058T (47%)
Japan (5 institutions) 2011 87.1% (176/202) A2058G (90.9%) Okada et al., 2012
A2058T (6.2%)
A2059G (2.3%)
A2058C (0.6%)
South Korea 2003 2.9% (1/34) A2058G (% ND) Hong et al., 2013
2006 14.7% (10/68) A2059G (% ND)
2010 47.2% (25/53)
2011 62.9% (44/70)
Taiwan 2010–2011 23.3% (14/60) A2058G (100%) Wu et al., 2013
EUROPE
Denmark 2010–2011 1.6% (6/365) ND Uldum et al., 2012
England and Wales 2010 0% (0/24) - Chalker et al., 2011
England and Wales 2011–2012 0% (0/12) - Chalker et al., 2012
England 2014–2015 9.3 (4/43) A2058G (100%) Brown et al., 2015
France 2005–2007 9.8% (5/51) A2058G (60%) Peuchant et al., 2009
A2059G (20%)
C2611G (20%)
France 2007–2010 3.4% (1/29) A2059G Pereyre et al., 2012
France 2011 8.3% (6/72) A2058G (67%) Pereyre et al., 2013
A2059G (16.5%)
A2062G (16.5%)
Germany 2003–2008 1.2% (2/167) A2058G Dumke et al., 2010
A2058C
Germany 2009–2012 3.6% (3/84) A2058G (100%) Dumke et al., 2013
Germany 2011–2012 3.1% (3/96) A2058G (100%) Dumke et al., 2015
Italy 2010 26% (11/43) A2058G (63.6%) Chironna et al., 2011
A2059G (36.4%)
Slovenia 2006–2014 1% (7/783) A2058G (100%) Kogoj et al., 2015
Switzerland 2011–2013 2% (1/50) A2058G Meyer Sauteur et al.,
2014
MIDDLE EAST
Israel 2010 30% (9/30) A2058G (100%) Averbuch et al., 2011
Israel 2010 22% (9/41) A2058G (100%) Pereyre et al., 2012
OCEANIA
Australia (Sydney) 2008–2012 3.3% (1/30) A2059G Xue et al., 2014
ND, not determined.
*Percentages calculated among the 561 resistant isolates collected over the 5 years.
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between 90 and 100% since 2003. Other Asian countries seem
less affected with resistance rates of 62.9, 47.1, and 23.3% in
South Korea, Hong-Kong and Taiwan, respectively (Table 2). It
should be noted that most reports regarding macrolide resistance
relate on hospitalized patients. It cannot be excluded that the
macrolide resistant rate in M. pneumoniae may be higher in
hospitalized patients in whom the resistant population may
be concentrated than in outpatients. However, comprehensive
studies on outpatients are not easily achievable because manyM.
pneumoniae infections such as mild tracheobronchitis are often
undiagnosed.
The high macrolide resistance rates in these countries are
certainly associated with antibiotic selective pressure because
of extensive macrolide use. This is supported by the highest
macrolide resistance rates being reported in countries with
extensive macrolide use such as Japan (Okada et al., 2012). In
addition, macrolide resistance was often associated with recent
receipt of macrolides, suggesting that a resistant subpopulation
may develop or expand during the course of macrolide therapy
within an individual patient (Averbuch et al., 2011; Cardinale
et al., 2011; Chironna et al., 2011; Hantz et al., 2012; Dumke
et al., 2014). Acquisition of resistance has first been documented
in patients receiving macrolides (Averbuch et al., 2011; Cardinale
et al., 2011) then confirmed using typing methods such as
adhesin P1 typing and multi-locus variable-number tandem-
repeat analysis (MLVA) in patients receiving macrolides (Hantz
et al., 2012; Dumke et al., 2014).
In North America, Europe, and Australia, rates of macrolide
resistance dramatically contrast with those in reports from Asia.
In the USA and Canada, rates have been recently reported
between 3.5 and 13.2% (Table 2). In Europe, rates have remained
below 10% except in Italy were a rate of 26% was observed on
a small number of M. pneumoniae-positive specimens collected
during an outbreak (Chironna et al., 2011).
All over the world, the A2058G transition largely
predominates over the A2059G substitution and mutations
at position 2611 and 2062 are rare (Table 2). Nevertheless,
the rarely reported A2058T transversion was found in 47% of
macrolide-resistant M. pneumoniae strains infecting children
during an outbreak in Fukuoka, Japan (Matsuda et al., 2013).
Despite the high proportion of the A2058G transition, no
association was reported between MLVA types and macrolide
resistance in several studies (Dégrange et al., 2009; Benitez
et al., 2012; Liu et al., 2012; Zhao et al., 2013a,b; Dumke et al.,
2015; Diaz et al., 2015a,b) indicating that macrolide resistance
is a result of the spread of multiple resistant clones. A possible
correlation was reported in Jerusalem, Israel, between the
MLVA type Z (7-4-5-7-2) and the A2058G-associated macrolide
resistance but the number of cases was limited (Pereyre et al.,
2012). Recently, an association between macrolide resistant
M. pneumoniae isolates and the MLVA type 4-5-7-2 was
suggested in China and Hong-Kong (Ho et al., 2015; Yan et al.,
2015). However the prevalence of this MLVA type was high
in these countries and the deletion of the unstable MPN1
marker from the MLVA method (Chalker et al., 2015) led to
a too weakly discriminant typing method to draw accurate
conclusions.
CLINICAL RELEVANCE OF M.
PNEUMONIAE MACROLIDE RESISTANCE
Regarding clinical presentation, no difference was observed
between patients infected by macrolide-resistant and macrolide-
sensitive M. pneumoniae. Clinical symptoms, pneumonia
severity, laboratory results, radiographic findings and
prognostic factors were similar regardless of the M. pneumoniae
susceptibility to macrolides (Matsubara et al., 2009; Cardinale
et al., 2013; Miyashita et al., 2013; Wu et al., 2013; Diaz et al.,
2015a). Most infections with macrolide-resistantM. pneumoniae
have been reported in children becauseM. pneumoniae infections
are more frequent in this population. Nevertheless, several adults
have also been evaluated (Cao et al., 2010; Ferguson et al., 2013;
Ho et al., 2015; Diaz et al., 2015a). To date, no difference has been
found in disease manifestations between children and adults
infected by macrolide-resistantM. pneumoniae.
As expected, the efficacy of macrolide treatment was
shown to be lower in patients infected with macrolide-
resistant isolates than in patients infected with macrolide-
sensitive isolates. Despite macrolide administration, the duration
of fever and cough, the duration of hospitalization and
antibiotic administration were significantly longer in patients
with macrolide-resistant M. pneumoniae infections. Moreover,
the persistence of symptoms led to change of antibiotic
prescription more often (Suzuki et al., 2006; Morozumi
et al., 2008; Matsubara et al., 2009; Cardinale et al., 2013;
Wu et al., 2013; Zhou et al., 2014). However, the clinical
relevance of macrolide resistance in patients was usually
limited to prolonging symptoms of the disease and not
increasing the risk of complications. Only a single study has
reported that the incidence of extrapulmonary complications
was higher in children with macrolide-resistant isolates and
that the radiological findings were more serious (Zhou et al.,
2014).
TREATMENT OF M. PNEUMONIAE
RESPIRATORY INFECTIONS
Macrolides and related antibiotics are the first-line treatment
of M. pneumoniae respiratory tract infections mainly because
of their low MIC against the bacteria, their low toxicity and
the absence of contraindication in young children. The agent
of first choice differs from country to country according to
different published guidelines and owing to the fact that not
all agents are available in all countries (Mandell et al., 2007;
Bradley et al., 2011; Harris et al., 2011; Woodhead et al.,
2011; Waites and Bébéar, 2013). The newer macrolides are
now often the preferred agents with a 7-to-14 day course of
oral clarithromycin or a 5-day course of oral azithromycin
for treatment of community-acquired pneumonia due to
M. pneumoniae (Waites and Bébéar, 2013). An appropriate
antimicrobial therapy usually shortens the symptomatic period
ofM. pneumoniae infections, and hastens radiological resolution
and recovery. However, using real-time PCR, it has been shown
that the median time for carriage of M. pneumoniae DNA was
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7 weeks after disease onset and that an adequate antibiotic
treatment did not shorten the period of persistence of M.
pneumoniae DNA in patient specimens (Nilsson et al., 2008).
No treatment recommendation is available for extrapulmonary
manifestations. In a few published case reports, macrolides
and fluoroquinolones, mainly levofloxacin, have successfully
been used (Scapini et al., 2008; Atkinson et al., 2011; Esposito
et al., 2011; Meyer Sauteur et al., 2012; Godron et al.,
2013).
In cases of macrolide-resistant M. pneumoniae strains,
alternative antibiotic treatment can be required, including
tetracyclines such as doxycycline and minocycline, or
fluoroquinolones, primarily levofloxacin, even though
fluoroquinolones and tetracyclines are contraindicated
in all children and in children <8 year-old, respectively.
Treatment lengths usually range between 7 and 14 days.
As expected, fluoroquinolone and tetracycline regimens
were shown to be more effective than macrolide regimens
in patients infected by macrolide-resistant M. pneumoniae
(Kawai et al., 2013; Miyashita et al., 2013). However,
macrolides appear clinically effective in some patients
infected by macrolide-resistant strains (Suzuki et al.,
2006; Matsubara et al., 2009; Cardinale et al., 2013). This
observation can be explained by the fact that M. pneumoniae
infections are often self-limited diseases and that the anti-
inflammatory effects of macrolides may improve clinical
symptoms.
In Europe, Oceania, and America, where the prevalence
of macrolide-resistant strains remains low, macrolides are the
drug of choice in children with M. pneumoniae respiratory
infections. Nevertheless, in these continents, clinicians should
be vigilant for macrolide treatment failure and consider using
alternative drugs if symptoms persist or if there are signs of
clinical deteriorations. In countries in which the prevalence
of macrolide-resistant strains is high, the replacement of
macrolides as the first choice treatment by tetracyclines or
fluoroquinolones was considered. However, surprisingly, in
Japan, according to the 2013 recommendations of the Japanese
Pediatric Society, macrolides remain the first-line treatment
despite macrolide resistance rates over 80%. In this country,
the efficacy of macrolides has to be evaluated by defervescence
48–72 h following the administration of these antimicrobials. In
pneumonia cases in which the initial macrolide therapy resulted
in failure, administration of alternative antimicrobial treatment,
either respiratory fluoroquinolones or tetracyclines, must be
considered. In contrast to Europe and to the United States,
oral tosufloxacin, a fluoroquinolone antibiotic, was approved in
Japan for pediatric use as a second line treatment in patients
with community-acquired pneumonia. Indeed, in one study
performed for the registration application of tosufloxacin in
Japan, the occurrence of joint paint was only 0.85% (2/235) and
there was no magnetic resonance imaging abnormal finding on
joints (data given by Dr T. Oishi, Japan). Another study on
83 pediatric patients with M. pneumoniae pneumonia treated
with tosufloxacin reported that side effects included mild
diarrhea, but that no patients had joint symptoms (Sakata,
2012). Although, tosufloxacin was les effective than minocycline
or doxycycline in achieving defervescence within 24 h and in
decreasing the DNA load of M. pneumoniae (Okada et al.,
2012; Kawai et al., 2013), its use is accepted in children under
8-year old. In countries where tosufloxacin is not available,
other available respiratory fluoroquinolones might be chosen
in severe cases despite contraindication. In children over 8-
year old and adults, minocycline can be used as second-line
treatment.
Although, no tetracycline or fluoroquinolone resistance has
been reported in clinical isolates to date, resistant strains have
been selected in vitro for both classes of drugs with target
mutations identified in mutants (Gruson et al., 2005; Degrange
et al., 2008). Thus, the risk of emergence of resistance in
clinical isolates exists, especially for fluoroquinolones, if these
antibiotics are inappropriately used. It should be noted that
clinical resistance to fluoroquinolones has already been reported
already in Mycoplasma genitalium, a urogenital mycoplasma
phylogenetically close to M. pneumoniae, in which macrolide
resistance mechanisms are similar to that of M. pneumoniae
(Couldwell et al., 2013; Bissessor et al., 2015).
Consequently to macrolide resistance in M. pneumoniae,
reevaluation of existing classes using and investigation of new
classes of antimicrobials may be required to get additional
treatment alternative beyond tetracyclines and fluoroquinolones,
especially in children under 8 year-old. Randomized therapeutic
trials will be necessary to establish guidelines regarding the
most appropriate molecule, dose and length of treatment
to use against the resistant strains. In the future, it will
also be interesting to evaluate the activity of streptogramin
combinations, such as oral pristinamycin, which has been shown
to retain activity against 23S rRNA M. pneumoniae in in
vitro mutants and in a few clinical isolates (Pereyre et al.,
2004a, 2007). Indeed, pristinamycin was reported to be active
on a few cases of genital infections by macrolide-resistant
fluoroquinolone-resistantM. genitalium isolates (Bissessor et al.,
2015). Although, additional studies on a large number of
strains are required, pristinamycin could become an alternative
antibiotic treatment in countries where this antibiotic is available
(Bebear, 2012).
CONCLUSION
Nowadays, M. pneumoniae macrolide resistance rates are
extremely high in Asia and remain moderate in Europe
and North America. Macrolide resistance detection using
accurate molecular methods should be considered in all M.
pneumoniae-positive specimens since it has both a direct
application in clinical practice and an epidemiological
surveillance interest. At the individual level, a rapid detection
of resistance-associated mutations would enable the prompt
prescription of an alternative antimicrobial regimen, especially
in case of persistent or recurrent M. pneumoniae infection.
At the community level, the high prevalence of macrolide-
resistant M. pneumoniae isolates in Asia underscore the
potential for rapid emergence of macrolide resistance within
M. pneumoniae in other parts of the world. Thus, further
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epidemiological studies are needed in Europe and the USA
to monitor macrolide resistance rates. Moreover, macrolide
stewardship may be needed for restricting the use of these
antibiotics, reduce unnecessary antibiotic prescribing, especially
in countries with remaining low macrolide resistant rates.
In Asia, the epidemiological surveillance of antibiotic
resistance would also be of interest to early detect potential
selections of fluoroquinolone- and tetracycline-resistant clinical
isolates associated with the increasing use of these classes of
antibiotics.
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